Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Teva Branded Pharmaceutical Products R&D, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
A pilot study to explore the utilization of the TEVA ProAir Digihaler rescue medication use and inhalation parameters to identify disease deterioration to help in the management of COPD patients in clinical practice. The study is designed to follow a small sample size of patients with COPD, monitor and collect inhalation parameters from the Digihaler dashboard, and changes in symptom control as measured by the COPD Assessment Test (CAT) to identify potential inhalation parameter thresholds that could be applied to the management of patients with COPD in clinical practice.
The trial is an unblinded open label single center study designed to identify trends in Peak Inspiratory Flow (PIF) rates and Rescue Albuterol Inhaler usage (Inhalations) that associate with disease deterioration as defined by worsening of symptoms and reduced lung function in patients with COPD.
The study will consist of a run-in period of approximately 2 weeks, a treatment period of 6 months and a follow-up period of 1 week. Twenty (20) patients with COPD requiring intermittent short acting beta agonist (SABA) rescue inhaler usage, but not requiring frequent SABA nebulizer rescue usage, will be enrolled.
After signing informed consent, patients will undergo a screening evaluation. During the run-in period, patients will continue on their COPD maintenance treatments, while discontinuing all previously prescribed periodic use rescue medications. Upon completion of screening, all patients will be dispensed a ProAir Digihaler to be used exclusively as their rescue medication throughout the duration of the study. During the run-in period all rescue inhaler usage will be electronically monitored and patient data from the Digihaler Dashboard will be downloaded every other business day basis (Monday, Wednesday and Friday).
At the completion of at least 2 weeks of run-in (with a minimum of at least 8 rescue inhaler usages) and with documentation of stable clinical status throughout run-in, the patient will return for baseline testing; including vital signs, health related quality of life and Anthonisen Exacerbation questionnaires, pre and post bronchodilator spirometry and 6-minute walk testing (see table/flow chart). Average Peak Inspiratory Flow (Baseline PIF) and average Number of Rescue Inhalations per day (Baseline Inhalations) will be determined from the Digihaler Dashboard Data downloads during run-in.
In the event that the patient does not meet number of rescue inhaler usages or does not have a stable clinical status during run-in, an additional 2 weeks of run-in may be obtained. If at the end of the extended run-in period so that Baseline PIF and Baseline Inhalations cannot be determined or the patient continues to be clinically unstable, the patient will be discontinued from the study. If the patient has an upper respiratory tract infection or COPD exacerbation during run-in, they will also be discontinued from the study. Patients may be re-screened one time at a later date, when stable.
Once run-in and baseline testing are complete, all patients will continue on their maintenance COPD medications and use the ProAir Digihaler rescue SABA exclusively for the next 6 months. Patients will be provided with paper forms of the CAT, BCSS and Anthonisen Exacerbation criteria, to be completed at home on a weekly basis and mailed to the research center upon completion).
Throughout the treatment period, all rescue inhaler usage will be electronically transmitted to, monitored at and downloaded from the Digihaler Dashboard by the research center on every other business day basis (Monday, Wednesday and Friday). At the completion of each Digihaler Dashboard Data Download, comparisons of Daily PIF (average PIF of all rescue inhalations in a day) and Daily Inhalations (number of rescue inhalations in a day) to Baseline PIF and Baseline Inhalations will be made.
All patients with Daily Inhalations exceeding Baseline Inhalations by ≥4 Inhalations per day and/or with a Daily PIF ≤80% of Baseline PIF for 2 consecutive days will be DEFINED as "at risk". For each "at risk" event, the patient will be contacted, their health status reviewed, and CAT and Anthonisen Exacerbation questionnaires will be administered. Based on symptoms, patients may also be advised to seek additional medical care.
All patients will be contacted on a monthly basis, irrespective of "risk" findings and seen in person every 3 months. All medication usage (including ProAir Digihaler medication usage), changes in medical care, healthcare contacts and usage, and any adverse events will be recorded. All office records for the intervening time period will be reviewed and Information for any non-office healthcare contacts and usage will be requested to provide detailed clinical information for comparison to Digihaler usage records.
At months 3 and 6 on treatment, all subjects will return to the research center, where vital signs, Anthonisen Exacerbation and CAT questionnaires, and post bronchodilator spirometry will be assessed. All medication usage (including ProAir Digihaler medication usage), changes in medical care, healthcare contacts and usage, and any adverse events will be recorded. All office records for the intervening time period will be reviewed and Information for any non-office healthcare contacts and usage will be requested to provide detailed clinical information for comparison to Digihaler usage records. Three (3) new ProAir Digihalers will be dispensed at month 3.
Throughout the treatment period, all rescue inhaler usage will be electronically monitored and downloaded from the Digihaler Dashboard by the research center on an every other business day basis (Monday, Wednesday and Friday). At the completion of each Digihaler Dashboard Data Download, comparisons of Daily PIF (average PIF of all rescue inhalations in a day) and Daily Inhalations (number of rescue inhalations in a day) to Baseline PIF and Baseline Inhalations will be made.
All patients with Daily Inhalations exceeding Baseline Inhalations by ≥4 Inhalations per day and/or with a Daily PIF ≤80% of Baseline PIF for 2 consecutive days will be DEFINED as "at risk". For each "at risk" event, the patient will be contacted, their health status reviewed, and CAT and Anthonisen Exacerbation questionnaires will be administered. Based on symptoms, patients may also be advised to seek additional medical care.
At the conclusion of the 6-month treatment period the patients will return to the research center for a final visit, returning all study medication not previously returned. The patient will be advised to resume usage of their prior rescue inhaler medication at that time. A telephone call will be made to the patient 1 week after their final in-person visit, to assess vital status and any adverse events that may have occurred subsequent to discontinuing the ProAir Digihaler.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ProAir Digihaler | Drug | Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use |
| |
| Digihaler | Device | Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use |
|
| Measure | Description | Time Frame |
|---|---|---|
| PIF Alerts and COPD Exacerbations | Presence of a Peak Inspiratory Flow (PIF) alert prior to a COPD Exacerbation Peak Inspiratory Flow (PIF) is the maximal inspiratory flow achieved during each patient inhalation of the Digihaler dry powder inhaler. PIF is automatically measured by the Digihaler dry powder inhaler during every inspiration of medication by a subject. Inspiratory flow is used to inhale respiratory medications into the lungs. A low inspiratory flow rate has been considered to place a COPD patient at risk for reducing medication inhalation and for other adverse outcomes. An acute fall in a patient's PIF may also be a marker of an impending change in a patient's condition. All acute COPD exacerbations were assessed by patient history, diaries and direct patient interviews. If a COPD Exacerbation had occurred, PIF measurements in the prior 2 weeks were assessed to determine if a PIF Alert, defined as a 20% fall in PIF from baseline for a minimum of 2 consecutive days, had occurred in the 2 weeks prior. | 6 months |
| Low PIF Alerts and Worsening CAT Score | Presence of a Low Peak Inspiratory Flow (PIF) alert, defined by an 20% reduction in PIF from baseline for a minimum of 2 consecutive days occurring in the 2 weeks prior to a worsening of a subject COPD Assessment Test Score (CAT, score range 0-40, clinically important difference defined as a change in CAT score of 2 or more over time with an increase in value identifying worsening disease). Peak Inspiratory Flow (PIF) is the maximal inspiratory flow achieved during each patient inhalation of the Digihaler dry powder inhaler. PIF is automatically measured and recorded by the Digihaler device during every inspiration of medication with the device. All PIF measures in the 2 weeks prior to any worsening of CAT were assessed and a PIF alert was identified as being present if PIF fell by ≥20% from baseline on 2 or more consecutive days in the 2 weeks prior to a worsening of CAT score event. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Rescue SABA Puff Use Alerts and COPD Exacerbations | Presence of a Rescue SABA Puff Use Alert, defined as an increase of 2 or more rescue inhaler puffs per day above baseline for 2 or more days in the 2 weeks prior to any COPD exacerbation. Rescue SABA Puff use is the counted and recorded use of the DIgihaler inhaler device each time the subject uses of the Digihaler device. | 6 months |
Not provided
Inclusion Criteria:
Documented history of COPD by ATS/GOLD criteria
Age > 45 years
Patient willing and able to:
Baseline spirometry consistent with COPD (post bronchodilator FEV1 < 80% predicted, FEV1/FVC <70%)
Use of albuterol inhaler as primary device for administration of rescue therapy
Reported use of rescue inhaler at least twice (4 inhalations) a week in the previous 6 months
Access to smartphone with blue-tooth and cellular/internet access
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults with COPD
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gary T Ferguson, M.D. | Pulmonary Research Institute of Southeast Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pulmonary Research Institute of Southeast Michigan | Farmington Hills | Michigan | 48336 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40384948 | Derived | Ferguson GT, Boe A, Hill TD, Yu D, Krishnamony M. Albuterol Digihaler in COPD Disease Management: A Real-World Study to Assess Digihaler Inhalation Parameters, Thresholds and Their Use to Identify Deterioration in Clinical Practice. Int J Chron Obstruct Pulmon Dis. 2025 May 13;20:1465-1476. doi: 10.2147/COPD.S519963. eCollection 2025. |
Not provided
Not provided
Data limited to study collaborative research organizations only
Not provided
Not provided
Not provided
Not provided
27 subjects were recruited and consented to enroll 20 subjects for 6 months of observation. 7 participants failed during run-in: 4 due to COPD exacerbation during run-in, 1 did not meet FEV1 entry criteria and 2 withdrew during run-in unrelated to study participation. All 20 participants enrolled in the study completed the study and were included in all analysis.Post study, subjects were stratified based on the occurrence of a COPD exacerbation during the study and analyzed accordingly.
Recruitment initiated May 19, 2021. Study completed June 20, 2022. The study was conducted at a single clinical research center, the Pulmonary Research Institute of Southeast Michigan.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Digihaler Device User | Single arm pilot study assessing the relationship of deterioration in COPD healthcare status (COPD exacerbations and/or worsening in COPD Assessment Test ≥2) to changes in physiologic parameters measured from usage of an albuterol Digihaler inhalation device, including peak inspiratory flow (PIF), extra inhaler puff usage per day and inhalation volume (InV) prior to any heaalthcare deterioration event. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
All subjects meeting inclusion/exclusion criteria
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Subjects With COPD Exacerbations | All subjects meeting inclusion exclusion criteria who had an exacerbation during the study |
| BG001 | Subjects With no COPD Exacerbation | All subjects meeting inclusion exclusion criteria who did not have an exacerbation during the study |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | PIF Alerts and COPD Exacerbations | Presence of a Peak Inspiratory Flow (PIF) alert prior to a COPD Exacerbation Peak Inspiratory Flow (PIF) is the maximal inspiratory flow achieved during each patient inhalation of the Digihaler dry powder inhaler. PIF is automatically measured by the Digihaler dry powder inhaler during every inspiration of medication by a subject. Inspiratory flow is used to inhale respiratory medications into the lungs. A low inspiratory flow rate has been considered to place a COPD patient at risk for reducing medication inhalation and for other adverse outcomes. An acute fall in a patient's PIF may also be a marker of an impending change in a patient's condition. All acute COPD exacerbations were assessed by patient history, diaries and direct patient interviews. If a COPD Exacerbation had occurred, PIF measurements in the prior 2 weeks were assessed to determine if a PIF Alert, defined as a 20% fall in PIF from baseline for a minimum of 2 consecutive days, had occurred in the 2 weeks prior. | This was an observational study with one treatment arm using a single study drug during the 6 months of study. All acute COPD exacerbation events meeting Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for an acute COPD exacerbation were assessed to determine if a PIF alert was present prior to the event. All subjects/ events were assessed as a treatment outcome (not a treatment arm). | Posted | Number | Low PIF Alert | 6 months | COPD Exacerbations |
Data was collected from consent to post study follow-up over approximately 7 months
All ad verse event descriptions and definitions are per clinicaltrials.gov
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Digihaler Device User | Single arm pilot study assessing the relationship of deterioration in COPD healthcare status (COPD exacerbations and/or worsening in COPD Assessment Test ≥2) to changes in physiologic parameters measured from usage of an albuterol Digihaler inhalation device, including peak inspiratory flow (PIF), extra inhaler puff usage per day and inhalation volume (InV) prior to any heaalthcare deterioration event. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| COPD Exacerbation | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Non-systematic Assessment | Worsening of COPD requiring hospitalization |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| COPD Exacerbation | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Non-systematic Assessment | COPD exacerbation requiring medical intervention |
This study was not designed for or intended to evaluate the use of the Digihaler to predict future clinical events in COPD patients. Rather, it was a non-powered exploratory pilot study designed to provide preliminary information and insights that might serve as the basis for future studies to assess whether the use of rescue albuterol in a digital inhaler device could be used as a predictive tool.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Gary T Ferguson, MD, Director | Pulmonary Research Institute of Southeast MIchigan | 248-478-6908 | garytferguson@msn.com |
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 30, 2021 | Jun 20, 2024 | Prot_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Mar 30, 2021 | Jun 20, 2024 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D000420 | Albuterol |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| Low IV Alerts and COPD Exacerbations | Presence of a Low Inhalation Volume (IV) alert, defined by a 20% fall in IV from baseline for 2 or more days in the 2 weeks prior to any COPD exacerbation. IV is the volume of air inhaled and measured during each patient inhalation use of the Digihaler device. | 6 months |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Baseline PIF | Peak Inspiratory Flow (PIF) is the maximal inspiratory flow a subject is able to generate while inspiring through a dry powder inhaler (or other inspiratory flow measurement tool) | Mean | Standard Deviation | L/min |
|
| COPD Exacerbations |
|
|
|
| Primary | Low PIF Alerts and Worsening CAT Score | Presence of a Low Peak Inspiratory Flow (PIF) alert, defined by an 20% reduction in PIF from baseline for a minimum of 2 consecutive days occurring in the 2 weeks prior to a worsening of a subject COPD Assessment Test Score (CAT, score range 0-40, clinically important difference defined as a change in CAT score of 2 or more over time with an increase in value identifying worsening disease). Peak Inspiratory Flow (PIF) is the maximal inspiratory flow achieved during each patient inhalation of the Digihaler dry powder inhaler. PIF is automatically measured and recorded by the Digihaler device during every inspiration of medication with the device. All PIF measures in the 2 weeks prior to any worsening of CAT were assessed and a PIF alert was identified as being present if PIF fell by ≥20% from baseline on 2 or more consecutive days in the 2 weeks prior to a worsening of CAT score event. | All worsening of CAT score events | Posted | Number | Low PIF Alert | 6 months | Worsening of CAT | Worsening of CAT |
|
|
|
| Secondary | Rescue SABA Puff Use Alerts and COPD Exacerbations | Presence of a Rescue SABA Puff Use Alert, defined as an increase of 2 or more rescue inhaler puffs per day above baseline for 2 or more days in the 2 weeks prior to any COPD exacerbation. Rescue SABA Puff use is the counted and recorded use of the DIgihaler inhaler device each time the subject uses of the Digihaler device. | All acute COPD exacerbation events meeting Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for an acute COPD exacerbation. | Posted | Number | Rescue SABA Puff Use Alert | 6 months | COPD Exacaerabations | COPD Exacaerabations |
|
|
|
| Secondary | Low IV Alerts and COPD Exacerbations | Presence of a Low Inhalation Volume (IV) alert, defined by a 20% fall in IV from baseline for 2 or more days in the 2 weeks prior to any COPD exacerbation. IV is the volume of air inhaled and measured during each patient inhalation use of the Digihaler device. | All acute COPD exacerbation events meeting Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for an acute COPD exacerbation. | Posted | Number | Low IV Alert | 6 months | COPD exacerbation | COPD exacerbation |
|
|
|
| 0 |
| 27 |
| 3 |
| 27 |
| 16 |
| 27 |
|
|
| Non respiratory adverse events | General disorders | MedDRA (10.0) | Non-systematic Assessment | Any ev ent qualifying as an adverse event that was not a COPD exacerbation AE |
|
Not provided
Not provided
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000588 |
| Amines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |